Ronald Levy, MD

Clinical Trials

• A Phase II Intratumoral Injection PF-3512676 plus Local Radiation in Low-Grade B-Cell Lymphomas Recruiting
• Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease Recruiting
• Genes in Predicting Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab and Combination Chemotherapy Recruiting
• Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous “Immunotransplant” for MCL Recruiting
• Ph II, Multicenter, Simon 2-Stage of R788 For Relapsed or Refractory T-Cell Lymphoma Recruiting
• Study of Bexxar Combined With External Beam Radiation Therapy for Patients With Relapsed, Bulky Non-Hodgkin's Lymphoma Recruiting
• Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma Terminated
• Phase I/II CPG 7909 + Local XRT in Recurrent Low-Grade Lymphomas No longer recruiting
• Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined with Local Radiation for Patients with Recurrent Mycosis Fungoides. Terminated
• Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells Completed
• High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma No longer recruiting
• Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma No longer recruiting